314 related articles for article (PubMed ID: 19307958)
21. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer.
Teramoto K; Asada Y; Ozaki Y; Suzumura Y; Nakano Y; Sawai S; Tezuka N; Inoue S; Fujino S
Cancer Chemother Pharmacol; 2012 Oct; 70(4):531-7. PubMed ID: 22864949
[TBL] [Abstract][Full Text] [Related]
24. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
Kosmas C; Tsavaris N; Koutras A; Makatsoris T; Mylonakis N; Tzelepis G; Dimitrakopoulos A; Spyropoulos K; Polyzos A; Karabelis A; Kalofonos HP
Oncology; 2005; 69(4):333-41. PubMed ID: 16282711
[TBL] [Abstract][Full Text] [Related]
26. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
Kentepozidis N; Kotsakis A; Soultati A; Agelaki S; Christophylakis Ch; Agelidou M; Chelis L; Papakotoulas P; Vamvakas L; Zafiriou Z; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2013 Mar; 71(3):605-12. PubMed ID: 23338050
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
[TBL] [Abstract][Full Text] [Related]
29. Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience.
Kocak M; Mayadagli A; Ozkan A; Parlak C; Demir O; Marti A; Dogan Eren M; Kaya S; Gumus M
J BUON; 2007; 12(4):471-6. PubMed ID: 18067204
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of combination chemotherapy with docetaxel and carboplatin for patients with advanced or metastatic non-small cell lung cancer.
Kasahara K; Kimura H; Shibata K; Araya T; Sone T; Oribe Y; Furusho S; Kita T; Shirasaki H; Oribe Y; Yoshimi Y; Ueda A; Tachibana H; Shintani H; Mizuguchi M; Nishi K; Fujimura M; Nakao S
Anticancer Res; 2006; 26(5B):3723-8. PubMed ID: 17094391
[TBL] [Abstract][Full Text] [Related]
31. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
[TBL] [Abstract][Full Text] [Related]
33. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Nogami N; Hotta K; Segawa Y; Takigawa N; Hosokawa S; Oze I; Fujii M; Ichihara E; Shibayama T; Tada A; Hamada N; Uno M; Tamaoki A; Kuyama S; Ikeda G; Osawa M; Takata S; Tabata M; Tanimoto M; Kiura K
Acta Oncol; 2012 Jul; 51(6):768-73. PubMed ID: 22283472
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer.
Kaira K; Takise A; Minato K; Iwasaki Y; Ishihara S; Takei Y; Tsuchiya S; Saito R; Sato K; Mori M
Anticancer Drugs; 2005 Apr; 16(4):455-60. PubMed ID: 15746583
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Lopes G; Rosado MF; Negret LM; Rocha-Lima C; Tolba K; Farfan N; Hamilton-Nelson K; Silva O; Roman E
Lung Cancer; 2006 Sep; 53(3):347-53. PubMed ID: 16844257
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.
Ohyanagi F; Yanagitani N; Kudo K; Kawano Y; Sakatani T; Tanimoto A; Nishizawa H; Horiike A; Hagiwara S; Horai T; Nishio M
Anticancer Res; 2014 Sep; 34(9):5153-8. PubMed ID: 25202107
[TBL] [Abstract][Full Text] [Related]
38. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
Kindwall-Keller T; Otterson GA; Young D; Neki A; Criswell T; Nuovo G; Soong R; Diasio R; Villalona-Calero MA
Clin Cancer Res; 2005 Mar; 11(5):1870-6. PubMed ID: 15756012
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Chen YM; Liu JM; Wu MF; Wu HW; Lin WC; Tsai CM; Perng RP; Whang-Peng J
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer.
Mori K; Kamiyama Y; Kondo T; Kano Y; Kodama T
Chemotherapy; 2005 May; 51(2-3):120-5. PubMed ID: 15886471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
